Company Registration No. SC162733 (Scotland)
CRAIGMARLOCH NURSERIES LTD
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
CRAIGMARLOCH NURSERIES LTD
COMPANY INFORMATION
Directors
K T Wilson BA (Hons) CA
A G McFarlane
C Begley
Secretary
I Devlin
Company number
SC162733
Registered office
Glasgow Road
Kilsyth
Glasgow
United Kingdom
G65 9BX
Auditor
Johnston Carmichael LLP
227 West George Street
Glasgow
G2 2ND
CRAIGMARLOCH NURSERIES LTD
CONTENTS
Page
Strategic report
1 - 2
Directors' report
3
Directors' responsibilities statement
4
Independent auditor's report
5 - 8
Group statement of comprehensive income
9
Group balance sheet
10
Company balance sheet
11
Group statement of changes in equity
12
Company statement of changes in equity
13
Group statement of cash flows
14
Notes to the financial statements
15 - 33
CRAIGMARLOCH NURSERIES LTD
STRATEGIC REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 1 -

The directors present the strategic report for the year ended 31 December 2024.

Fair review of the business

The business has expanded and evolved significantly over the past five years. During this period, we have witnessed some of the most challenging, demanding, and exciting times in the history of the group. We have invested to expand our growing and production facilities to allow us to significantly increase our own grown products. The management team and staff adapted well to all the challenges, with there being significant learning opportunities which only stands to make the business stronger as we move forward on to other exciting development plans.

 

2024, like all years, brought its own set of challenges due to cost of living, inflation not meeting BOE targets and interest rates not falling as much as expected, all of which continue to impact our supply chain. Despite these challenges revenue growth through 2024 was very positive. Weather continues to play an important part during the key trading period for the business which is March to July. In 2024 during this period the weather was very changeable with prolonged periods of heavier precipitation which had a negative impact on the sales volume we would expect. Moving into 2025 we are focusing on increasing the volume we can produce to allow us to target larger commercial growing contracts. Our available space will impact this, but we continue to add new growing spaces to accommodate this expansion. Contracts and reserves for 2025 continue to be very strong.

Principal risks and uncertainties

Over the past twelve months we have seen continued pressure on wage rates, interest rate adjustments, supplier pricing and increased competition in the marketplace, however being in the position to increase our own production gives us great control over this risk factor. We are now able to compete and supply to a wider customer base which is giving the business the growth that we require. Interest rate changes will need to be monitored as we move forward to assess their impact on consumer spending and any investment decision that we take. All these factors will impact on the business performance and development.

 

Brexit has caused several issues within the industry most notably from an administrative side, but it has also resulted in more UK customers looking to source products within the UK. Our increasingly expanding range and volume of products are allowing us to help support this demand and increase our revenue.

Development and performance

The management team have a five-year plan that we are working towards, and this is reviewed on a six-month basis. It is our short-term goal to continue to develop new product ranges while continuing to increase volumes on our best-selling lines. We see our growth coming from increased production and supplying throughout the UK. We will continue to explore acquisition opportunities both in the supply chain, marketplace, or competitors.

Key performance indicators

The group regard revenue, gross profit margin and net profit margin as the key financial performance indicators. Revenue has increased from 2023 returning our highest revenue position in the company history, eclipsing the prior record high in 2023 by 10.4%. Gross and net profit margin have improved year on year despite the impact of increased wage costs and interest rates. The continued investment in stock and increased working capital cycling from our production is a primary focus on 2025. Performance was broadly in line with budget and therefore within our expectation.

 

Supplier pricing pressures were evident as we moved from 2023 to 2024, coupled with increased inflation and wage rates we have witnessed pressure on net margin levels. We have a diversified product and supplier base but most significantly, our ability to be self-sufficient on certain product categories provides a competitive advantage in the marketplace. The past four years have been extremely challenging but as a management team we have moved the business forward significantly. We are investing in our staff, our infrastructure, and our supply chain. Our aim is to be the most successful grower and wholesaler within the UK marketplace.

CRAIGMARLOCH NURSERIES LTD
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 2 -
Sustainability policy

As a business we are committed to and enjoy finding ways that we can reduce the impact of our business on the environment. Sustainable business practices are at the heart of all key decisions. Over the past five years we have made significant steps forward in our objective to operate our most sustainable business model. Outlined below are some of the key policies we have implemented:

 

 

We will continue to monitor and move forward with new sustainable business practices each year as we understand the importance of this process. We intend to commission a report that will set us on a path to net zero in the next five years.

On behalf of the board

K T Wilson BA (Hons) CA
Director
30 September 2025
CRAIGMARLOCH NURSERIES LTD
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 3 -

The directors present their annual report and financial statements for the year ended 31 December 2024.

Principal activities

The principal activity of the group continued to be that of the growing and sale of shrubs, plants and trees to other commercial outlets and commercial landscapers.

Results and dividends

The results for the year are set out on page 9.

Ordinary dividends were paid amounting to £12,000 (2023: £12,000). The directors do not recommend payment of a further dividend.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

K T Wilson BA (Hons) CA
A G McFarlane
C Begley
Qualifying third party indemnity provisions

The company has made qualifying third party indemnity provisions for the benefit of its directors during the year. These provisions remain in force at the reporting date.

Future developments

The group has chosen in accordance with Companies Act 2006, s. 414C(11) to set out in the strategic report information required by Large and Medium-sized Companies and Groups (Accounts and Reports) Regulations 2008, Sch. 7 to be contained in the directors' report. It has done so in respect of future developments.

Auditor

The auditor, Johnston Carmichael LLP, is deemed to be reappointed under section 487(2) of the Companies Act 2006.

Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the auditor of the company is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the auditor of the company is aware of that information.

On behalf of the board
K T Wilson BA (Hons) CA
Director
30 September 2025
CRAIGMARLOCH NURSERIES LTD
DIRECTORS' RESPONSIBILITIES STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 4 -

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.

 

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the group and company, and of the profit or loss of the group for that period. In preparing these financial statements, the directors are required to:

 

 

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the group’s and company’s transactions and disclose with reasonable accuracy at any time the financial position of the group and company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the group and company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

CRAIGMARLOCH NURSERIES LTD
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF CRAIGMARLOCH NURSERIES LTD
- 5 -
Opinion

We have audited the financial statements of Craigmarloch Nurseries Ltd (the 'parent company') and its subsidiaries (the 'group') for the year ended 31 December 2024 which comprise the group statement of comprehensive income, the group balance sheet, the company balance sheet, the group statement of changes in equity, the company statement of changes in equity, the group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

 

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent company’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

 

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

 

We have nothing to report in this regard.

CRAIGMARLOCH NURSERIES LTD
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF CRAIGMARLOCH NURSERIES LTD
- 6 -

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

 

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the group and the parent company and their environment obtained in the course of the audit, we have not identified material misstatements in the strategic report and the directors' report.

 

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

 

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

 

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at: http://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

Extent to which the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

We assessed whether the engagement team collectively had the appropriate competence and capabilities to identify or recognise non-compliance with laws and regulations by considering their experience, past performance and support available.

All engagement team members were briefed on relevant identified laws and regulations and potential fraud risks at the planning stage of the audit. Engagement team members were reminded to remain alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

CRAIGMARLOCH NURSERIES LTD
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF CRAIGMARLOCH NURSERIES LTD
- 7 -

Extent the audit was considered capable of detecting irregularities, including fraud (continued)

We obtained an understanding of the legal and regulatory frameworks that are applicable to the group and the parent company and the sector in which they operate, focusing on those provisions that had a direct effect on the determination of material amounts and disclosures in the financial statements. The most relevant frameworks we identified include:

 

We gained an understanding of how the group and the parent company are complying with these laws and regulations by making enquiries of management and those charged with governance.

We assessed the susceptibility of the group’s financial statements to material misstatement, including how fraud might occur, by meeting with management and those charged with governance to understand where it was considered there was susceptibility to fraud. This evaluation also considered how management and those charged with governance were remunerated and whether this provided an incentive for fraudulent activity. We considered the overall control environment and how management and those charged with governance oversee the implementation and operation of controls. In areas of the financial statements where the risks were considered to be higher, we performed procedures to address each identified risk. We identified a heightened fraud risk in relation to:

 

In addition to the above, the following procedures were performed to provide reasonable assurance that the financial statements were free of material fraud or error:

Our audit procedures were designed to respond to the risk of material misstatements in the financial statements, recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve intentional concealment, forgery, collusion, omission or misrepresentation. There are inherent limitations in the audit procedures performed and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we would become aware of it.

CRAIGMARLOCH NURSERIES LTD
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF CRAIGMARLOCH NURSERIES LTD
- 8 -

Use of our report

This report is made solely to the company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

James Hamilton (Senior Statutory Auditor)
For and on behalf of Johnston Carmichael LLP
30 September 2025
227 West George Street
Glasgow
G2 2ND
CRAIGMARLOCH NURSERIES LTD
GROUP STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2024
- 9 -
2024
2023
Notes
£
£
Turnover
3
19,581,671
17,733,641
Cost of sales
(14,514,541)
(13,676,138)
Gross profit
5,067,130
4,057,503
Administrative expenses
(4,491,078)
(3,584,956)
Other operating income
252,294
202,815
Operating profit
4
828,346
675,362
Interest receivable and similar income
8
822
-
0
Interest payable and similar expenses
9
(306,237)
(299,665)
Profit before taxation
522,931
375,697
Tax on profit
10
(213,255)
(131,823)
Profit for the financial year
24
309,676
243,874
Other comprehensive income
Currency translation differences
12,241
(1,509)
Total comprehensive income for the year
321,917
242,365
Profit for the financial year is all attributable to the owners of the parent company.
Total comprehensive income for the year is all attributable to the owners of the parent company.
CRAIGMARLOCH NURSERIES LTD
GROUP BALANCE SHEET
AS AT
31 DECEMBER 2024
31 December 2024
- 10 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
12
8,953,780
8,317,106
Current assets
Stocks
15
4,142,145
4,802,391
Debtors
16
3,254,778
813,448
Cash at bank and in hand
21,586
53,840
7,418,509
5,669,679
Creditors: amounts falling due within one year
17
(6,886,698)
(5,588,204)
Net current assets
531,811
81,475
Total assets less current liabilities
9,485,591
8,398,581
Creditors: amounts falling due after more than one year
18
(5,245,992)
(4,651,527)
Provisions for liabilities
Deferred tax liability
21
1,030,418
847,790
(1,030,418)
(847,790)
Net assets
3,209,181
2,899,264
Capital and reserves
Called up share capital
23
127
127
Revaluation reserve
24
543,406
543,406
Profit and loss reserves
24
2,665,648
2,355,731
Total equity
3,209,181
2,899,264
The financial statements were approved by the board of directors and authorised for issue on 30 September 2025 and are signed on its behalf by:
30 September 2025
K T Wilson BA (Hons) CA
Director
CRAIGMARLOCH NURSERIES LTD
COMPANY BALANCE SHEET
AS AT 31 DECEMBER 2024
31 December 2024
- 11 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
12
8,947,442
8,317,106
Investments
13
86
86
8,947,528
8,317,192
Current assets
Stocks
15
4,069,851
4,802,391
Debtors
16
3,227,205
796,469
Cash at bank and in hand
16,217
50,427
7,313,273
5,649,287
Creditors: amounts falling due within one year
17
(6,561,407)
(5,422,000)
Net current assets
751,866
227,287
Total assets less current liabilities
9,699,394
8,544,479
Creditors: amounts falling due after more than one year
18
(5,245,992)
(4,651,527)
Provisions for liabilities
Deferred tax liability
21
1,030,418
847,790
(1,030,418)
(847,790)
Net assets
3,422,984
3,045,162
Capital and reserves
Called up share capital
23
127
127
Revaluation reserve
24
543,406
543,406
Profit and loss reserves
24
2,879,451
2,501,629
Total equity
3,422,984
3,045,162

As permitted by s408 Companies Act 2006, the company has not presented its own profit and loss account and related notes. The company’s profit for the year was £389,822 (2023 - £389,564 profit).

The financial statements were approved by the board of directors and authorised for issue on 30 September 2025 and are signed on its behalf by:
30 September 2025
K T Wilson BA (Hons) CA
Director
Company Registration No. SC162733
CRAIGMARLOCH NURSERIES LTD
GROUP STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024
- 12 -
Share capital
Revaluation reserve
Profit and loss reserves
Total
Notes
£
£
£
£
Balance at 1 January 2023
127
543,406
2,125,366
2,668,899
Year ended 31 December 2023:
Profit for the year
-
-
243,874
243,874
Other comprehensive income:
Currency translation differences
-
-
(1,509)
(1,509)
Total comprehensive income for the year
-
-
242,365
242,365
Dividends
11
-
-
(12,000)
(12,000)
Balance at 31 December 2023
127
543,406
2,355,731
2,899,264
Year ended 31 December 2024:
Profit for the year
-
-
309,676
309,676
Other comprehensive income:
Currency translation differences
-
-
12,241
12,241
Total comprehensive income for the year
-
-
321,917
321,917
Dividends
11
-
-
(12,000)
(12,000)
Balance at 31 December 2024
127
543,406
2,665,648
3,209,181
CRAIGMARLOCH NURSERIES LTD
COMPANY STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024
- 13 -
Share capital
Revaluation reserve
Profit and loss reserves
Total
Notes
£
£
£
£
Balance at 1 January 2023
127
543,406
2,124,064
2,667,597
Year ended 31 December 2023:
Profit and total comprehensive income for the year
-
-
389,565
389,565
Dividends
11
-
-
(12,000)
(12,000)
Balance at 31 December 2023
127
543,406
2,501,629
3,045,162
Year ended 31 December 2024:
Profit and total comprehensive income for the year
-
-
389,822
389,822
Dividends
11
-
-
(12,000)
(12,000)
Balance at 31 December 2024
127
543,406
2,879,451
3,422,984
CRAIGMARLOCH NURSERIES LTD
GROUP STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 14 -
2024
2023
Notes
£
£
£
£
Cash flows from operating activities
Cash generated from/(absorbed by) operations
28
386,697
(615,426)
Interest paid
(306,238)
(299,665)
Income taxes paid
-
(727)
Net cash inflow/(outflow) from operating activities
80,459
(915,818)
Investing activities
Purchase of tangible fixed assets
(1,034,349)
(454,150)
Interest received
822
-
0
Net cash used in investing activities
(1,033,527)
(454,150)
Financing activities
Proceeds of new bank loans
800,000
3,500,000
Repayment of bank loans
(231,820)
(2,084,567)
Payment of finance leases obligations
(273,099)
(221,057)
Dividends paid to equity shareholders
(12,000)
(12,000)
Net cash generated from financing activities
283,081
1,182,376
Net decrease in cash and cash equivalents
(669,987)
(187,592)
Cash and cash equivalents at beginning of year
53,719
241,311
Cash and cash equivalents at end of year
(616,268)
53,719
Relating to:
Cash at bank and in hand
21,586
53,840
Bank overdrafts included in creditors payable within one year
(637,854)
(121)
CRAIGMARLOCH NURSERIES LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 15 -
1
Accounting policies
Company information

Craigmarloch Nurseries Ltd (“the company”) is a private limited company domiciled and incorporated in Scotland. The registered office is Glasgow Road, Kilsyth, Glasgow, United Kingdom, G65 9BX.

 

The group consists of Craigmarloch Nurseries Ltd and all of its subsidiaries.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties. The principal accounting policies adopted are set out below.

The company is a qualifying entity for the purposes of FRS 102 and has taken advantage of the exemption available from the requirement to present a company only cash flow statement and related notes and disclosures.

1.2
Business combinations

In the parent company financial statements, the cost of a business combination is the fair value at the acquisition date of the assets given, equity instruments issued and liabilities incurred or assumed, plus costs directly attributable to the business combination. The excess of the cost of a business combination over the fair value of the identifiable assets, liabilities and contingent liabilities acquired is recognised as goodwill. The cost of the combination includes the estimated amount of contingent consideration that is probable and can be measured reliably, and is adjusted for changes in contingent consideration after the acquisition date. Provisional fair values recognised for business combinations in previous periods are adjusted retrospectively for final fair values determined in the 12 months following the acquisition date. Investments in subsidiaries, joint ventures and associates are accounted for at cost less impairment.

 

Deferred tax is recognised on differences between the value of assets (other than goodwill) and liabilities recognised in a business combination accounted for using the purchase method and the amounts that can be deducted or assessed for tax, considering the manner in which the carrying amount of the asset or liability is expected to be recovered or settled. The deferred tax recognised is adjusted against goodwill or negative goodwill.

1.3
Basis of consolidation

The consolidated group financial statements consist of the financial statements of the parent company Craigmarloch Nurseries Ltd together with all entities controlled by the parent company (its subsidiaries).

 

All financial statements are made up to 31 December 2024. Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used into line with those used by other members of the group.

 

All intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.

Subsidiaries are consolidated in the group’s financial statements from the date that control commences until the date that control ceases.

CRAIGMARLOCH NURSERIES LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 16 -
1.4
Going concern

The UK Companies Act requires the Board to consider whether it remains appropriate to adopt the going concern basis of accounting in preparing these financial statements, and to identify any material uncertainties to the Group's ability to continue as a going concern over a period of at least twelve months from the date of approval of the financial statements.  In making this assessment, the board has taken into consideration the Group's business activities, together with factors likely to affect its future development, performance and principal risks and uncertainties.

 

At the time of approving the financial statements, the directors, having considered recent financial trends, available forecasts, cash resources and facilities available to the Group, have concluded that there is no material uncertainty arising in relation to going concern. There is thus a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future.  Therefore, the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.5
Turnover

Turnover relates to the sale of shrubs, plants and trees and is recognised at the fair value of the consideration received or receivable for goods provided net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch or collection of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.6
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Freehold land and buildings
2% straight line
Plant and equipment
10 years straight line
Motor vehicles
5 years straight line
Software development
10% straight line

Assets in the course of construction are not depreciated.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of comprehensive income.

1.7
Fixed asset investments

Equity investments are measured at fair value through profit or loss, except for those equity investments that are not publicly traded and whose fair value cannot otherwise be measured reliably, which are recognised at cost less impairment until a reliable measure of fair value becomes available.

 

In the parent company financial statements, investments in subsidiaries are initially measured at cost and subsequently measured at cost less any accumulated impairment losses.

A subsidiary is an entity controlled by the group. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

CRAIGMARLOCH NURSERIES LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 17 -
1.8
Impairment of fixed assets

At each reporting period end date, the group reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

1.9
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in the statement of comprehensive income. Reversals of impairment losses are also recognised in the statement of comprehensive income.

1.10
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.11
Financial instruments

The group has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the group's balance sheet when the group becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset and the net amounts presented in the financial statements when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include certain debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

CRAIGMARLOCH NURSERIES LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 18 -
Impairment of financial assets

Financial assets are assessed for indicators of impairment at each reporting end date.

 

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in the statement of comprehensive income.

 

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in the statement of comprehensive income.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the group transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the group after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including certain creditors, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the group's contractual obligations expire or are discharged or cancelled.

1.12
Equity instruments

Equity instruments issued by the group are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the group.

CRAIGMARLOCH NURSERIES LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 19 -
1.13
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the statement of comprehensive income because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The group’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the statement of comprehensive income, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset if, and only if, there is a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.14
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.15
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.16
Leases

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.

 

Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to the statement of comprehensive income so as to produce a constant periodic rate of interest on the remaining balance of the liability.

Rentals payable under operating leases, including any lease incentives received, are charged to the statement of comprehensive income on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leased asset are consumed.

CRAIGMARLOCH NURSERIES LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 20 -
1.17
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in the statement of comprehensive income within other operating income.

2
Judgements and key sources of estimation uncertainty

In the application of the group’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Key sources of estimation uncertainty

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows.

Stock valuation

The group's stock is carried at the lower of cost and net realisable value. The assessment of net realisable value contains estimation uncertainty that management must consider when establishing if products or product lines require impairment below cost. At each reporting date, management make an assessment for impairment and in doing so consider slow moving, damaged or diseased stock lines.

 

The carrying value of stocks at the reporting date are outlined at note 15.

Carrying value of tangible fixed assets

The group’s freehold land and buildings are carried at valuation. The directors are therefore required to consider the carrying value of land and buildings each year to ensure that they remain appropriately stated. In performing this review, the directors consider a number of factors including completing valuation in Use calculations to ensure properties are not impaired.

 

The carrying value of freehold land and buildings it outlined at note 12.

CRAIGMARLOCH NURSERIES LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 21 -
3
Turnover and other revenue
2024
2023
£
£
Turnover analysed by class of business
Sale of plants and flowers
14,383,650
11,597,443
Non-plant sales
5,198,021
6,136,198
19,581,671
17,733,641
2024
2023
£
£
Turnover analysed by geographical market
UK
17,688,653
16,020,409
Europe
1,893,018
1,713,232
19,581,671
17,733,641
2024
2023
£
£
Other significant revenue
Interest income
822
-
Foreign exchange gains
252,294
202,785
4
Operating profit
2024
2023
£
£
Operating profit for the year is stated after charging:
Exchange differences apart from those arising on financial instruments measured at fair value through profit or loss
6,677
-
Depreciation of owned tangible fixed assets
191,381
260,326
Depreciation of tangible fixed assets held under finance leases
206,294
136,853
Operating lease charges
111,799
15,223
5
Auditor's remuneration
2024
2023
Fees payable to the company's auditor and associates:
£
£
For audit services
Audit of the financial statements of the group and company
18,700
13,500
CRAIGMARLOCH NURSERIES LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 22 -
6
Employees

The average monthly number of persons (including directors) employed by the group and company during the year was:

Group
Company
2024
2023
2024
2023
Number
Number
Number
Number
Administration
16
18
16
15
Nursery
83
88
83
88
Total
99
106
99
103

Their aggregate remuneration comprised:

Group
Company
2024
2023
2024
2023
£
£
£
£
Wages and salaries
2,777,787
2,260,170
2,685,885
2,149,992
Social security costs
210,557
184,954
210,557
184,954
Pension costs
32,522
25,744
32,522
25,744
3,020,866
2,470,868
2,928,964
2,360,690
7
Directors' remuneration
2024
2023
£
£
Remuneration for qualifying services
164,160
222,609
Company pension contributions to defined contribution schemes
1,182
793
165,342
223,402

The number of directors for whom retirement benefits are accruing under defined contribution schemes amounted to 1 (2023 - 1).

Remuneration disclosed above includes the following amounts paid to the highest paid director:
2024
2023
£
£
Remuneration for qualifying services
n/a
109,387

The aggregated director's remuneration for the year did not exceed £200,000 therefore no disclosure has been made.

CRAIGMARLOCH NURSERIES LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 23 -
8
Interest receivable and similar income
2024
2023
£
£
Interest income
Interest on bank deposits
822
-
0
9
Interest payable and similar expenses
2024
2023
£
£
Interest on bank overdrafts and loans
268,839
204,375
Other finance charges
-
52,346
Interest on finance leases and hire purchase contracts
37,398
42,944
Total finance costs
306,237
299,665
10
Taxation
2024
2023
£
£
Current tax
UK corporation tax on profits for the current period
30,342
-
0
Adjustments in respect of prior periods
285
100
Total current tax
30,627
100
Deferred tax
Origination and reversal of timing differences
168,496
159,096
Adjustment in respect of prior periods
14,132
(27,373)
Total deferred tax
182,628
131,723
Total tax charge
213,255
131,823
CRAIGMARLOCH NURSERIES LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
10
Taxation
(Continued)
- 24 -

The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:

2024
2023
£
£
Profit before taxation
522,931
375,697
Expected tax charge based on the standard rate of corporation tax in the UK of 25.00% (2023: 23.52%)
130,733
88,364
Tax effect of expenses that are not deductible in determining taxable profit
4,278
4,558
Adjustments in respect of prior years
285
(85,167)
Effect of change in corporation tax rate
-
9,415
Deferred tax adjustments in respect of prior years
14,132
(27,373)
Fixed asset differences
43,005
45,159
Other tax adjustments and reliefs
20,822
96,867
Taxation charge
213,255
131,823

 

11
Dividends
2024
2023
Recognised as distributions to equity holders:
£
£
Final paid
12,000
12,000
CRAIGMARLOCH NURSERIES LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 25 -
12
Tangible fixed assets
Group
Freehold land and buildings
Assets under construction
Plant and equipment
Motor vehicles
Software development
Total
£
£
£
£
£
£
Cost or valuation
At 1 January 2024
6,981,847
336,277
2,050,959
553,236
198,637
10,120,956
Additions
171,127
546,529
246,544
-
0
70,149
1,034,349
Disposals
-
0
-
(15,070)
(8,440)
-
0
(23,510)
At 31 December 2024
7,152,974
882,806
2,282,433
544,796
268,786
11,131,795
Depreciation and impairment
At 1 January 2024
530,124
-
0
926,150
301,037
46,539
1,803,850
Depreciation charged in the year
132,898
-
0
176,688
73,157
14,932
397,675
Eliminated in respect of disposals
-
0
-
0
(15,070)
(8,440)
-
0
(23,510)
At 31 December 2024
663,022
-
0
1,087,768
365,754
61,471
2,178,015
Carrying amount
At 31 December 2024
6,489,952
882,806
1,194,665
179,042
207,315
8,953,780
At 31 December 2023
6,451,723
336,277
1,124,809
252,199
152,098
8,317,106
Company
Freehold land and buildings
Assets under construction
Plant and equipment
Motor vehicles
Software development
Total
£
£
£
£
£
£
Cost or valuation
At 1 January 2024
6,981,847
336,277
2,050,959
553,236
198,637
10,120,956
Additions
171,127
546,529
239,218
-
0
70,149
1,027,023
Disposals
-
0
-
(15,070)
(8,440)
-
0
(23,510)
At 31 December 2024
7,152,974
882,806
2,275,107
544,796
268,786
11,124,469
Depreciation and impairment
At 1 January 2024
530,124
-
0
926,150
301,037
46,539
1,803,850
Depreciation charged in the year
132,898
-
0
175,700
73,157
14,932
396,687
Eliminated in respect of disposals
-
0
-
0
(15,070)
(8,440)
-
0
(23,510)
At 31 December 2024
663,022
-
0
1,086,780
365,754
61,471
2,177,027
Carrying amount
At 31 December 2024
6,489,952
882,806
1,188,327
179,042
207,315
8,947,442
At 31 December 2023
6,451,723
336,277
1,124,809
252,199
152,098
8,317,106
CRAIGMARLOCH NURSERIES LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
12
Tangible fixed assets
(Continued)
- 26 -

The net carrying value of tangible fixed assets includes the following in respect of assets held under finance leases or hire purchase contracts.

Group
Company
2024
2023
2024
2023
£
£
£
£
Plant and equipment
658,046
638,454
658,046
638,454
Motor vehicles
158,031
214,083
158,031
214,083
Software development
-
100,923
-
100,923
816,077
1,087,987
816,077
1,087,987

In assessing the fair value, the directors have considered independent valuations carried out in September 2023. These were performed for the purposes of renewing bank funding and in the view of the directors did not take into consideration the specialist horticultural nature of the group. The Directors also prepared a valuation at 31 December 2024 based on continued use of the property in the operation.

If assets adjusted from historic cost to fair value were measured using the cost model, the carrying amounts would be as follows:

2024
2023
£
£
Group
Cost
3,213,032
3,213,032
Accumulated depreciation
(709,751)
(645,490)
Carrying value
2,503,281
2,567,542
13
Fixed asset investments
Group
Company
2024
2023
2024
2023
Notes
£
£
£
£
Investments in subsidiaries
14
-
0
-
0
86
86
Movements in fixed asset investments
Company
Shares in subsidiaries
£
Cost or valuation
At 1 January 2024 and 31 December 2024
86
Carrying amount
At 31 December 2024
86
At 31 December 2023
86
CRAIGMARLOCH NURSERIES LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 27 -
14
Subsidiaries

Details of the company's subsidiaries at 31 December 2024 are as follows:

Name of undertaking
Registered office
Nature of business
Class of
% Held
shares held
Direct
Craigmarloch BV
See below
Wholesaler of plants and flowers
Ordinary
100.00

The registered office of Craigmarloch B.V. is Hoekeindseweg 194, 2665KH, Bleiswijk

15
Stocks
Group
Company
2024
2023
2024
2023
£
£
£
£
Finished goods and goods for resale
4,142,145
4,802,391
4,069,851
4,802,391
16
Debtors
Group
Company
2024
2023
2024
2023
Amounts falling due within one year:
£
£
£
£
Trade debtors
438,666
557,879
415,761
557,014
Other debtors
27,791
247,573
23,123
231,459
Prepayments and accrued income
2,788,321
7,996
2,788,321
7,996
3,254,778
813,448
3,227,205
796,469
17
Creditors: amounts falling due within one year
Group
Company
2024
2023
2024
2023
Notes
£
£
£
£
Bank loans and overdrafts
19
823,365
347,130
823,365
347,130
Obligations under finance leases
20
260,377
313,353
260,377
313,353
Trade creditors
2,423,849
1,708,866
2,350,995
1,629,640
Amounts owed to group undertakings
-
0
-
0
2,333
78,790
Corporation tax payable
31,360
-
0
29,863
-
0
Other taxation and social security
211,747
294,071
211,747
294,071
Other creditors
3,059,711
2,830,708
2,816,946
2,677,341
Accruals and deferred income
76,289
94,076
65,781
81,675
6,886,698
5,588,204
6,561,407
5,422,000

Obligations under finance leases are secured against the underlying asset concerned.

CRAIGMARLOCH NURSERIES LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 28 -
18
Creditors: amounts falling due after more than one year
Group
Company
2024
2023
2024
2023
Notes
£
£
£
£
Bank loans
19
4,030,614
3,152,991
4,030,614
3,152,991
Obligations under finance leases
20
174,595
394,718
174,595
394,718
Other creditors
1,040,783
1,103,818
1,040,783
1,103,818
5,245,992
4,651,527
5,245,992
4,651,527

Obligations under finance leases are secured against the underlying asset concerned.

 

Included within other creditors are interest free loans granted by the directors and related parties of £1,040,783 (2023 - £1,112,427) and £242,765 (2023 - £2,667,147) respectively.

 

The directors and related parties have confirmed that the amounts will not be called for repayment within the 12 months from the balance sheet date.

Amounts included above which fall due after five years are as follows:
Payable by instalments
-
1,198,330
-
1,198,330
19
Loans and overdrafts
Group
Company
2024
2023
2024
2023
£
£
£
£
Bank loans
4,216,125
3,500,000
4,216,125
3,500,000
Bank overdrafts
637,854
121
637,854
121
4,853,979
3,500,121
4,853,979
3,500,121
Payable within one year
823,365
347,130
823,365
347,130
Payable after one year
4,030,614
3,152,991
4,030,614
3,152,991

Bank loans outlined above are secured by a floating charge over the company's assets. The bank loan is also subject to a cross guarantee provided by two connected companies with the guarantee supported by a debenture and by floating charges over the assets of these connected entities.

 

The loan incur interest at a floating rate basis under which the interest rate will never be less than the margin of 2% per annum. The term loan is 5 years.

CRAIGMARLOCH NURSERIES LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 29 -
20
Finance lease obligations
Group
Company
2024
2023
2024
2023
£
£
£
£
Future minimum lease payments due under finance leases:
Within one year
260,377
313,352
260,377
313,352
In two to five years
165,075
394,719
165,075
394,719
In over five years
9,520
-
0
9,520
-
0
434,972
708,071
434,972
708,071

Finance lease payments represent rentals payable by the company or group for certain items of plant and machinery. Leases include purchase options at the end of the lease period, and no restrictions are placed on the use of the assets. The average lease term is 3-5 years. All leases are on a fixed repayment basis and no arrangements have been entered into for contingent rental payments.

21
Deferred taxation

The following are the major deferred tax liabilities and assets recognised by the group and company, and movements thereon:

Liabilities
Liabilities
2024
2023
Group
£
£
Accelerated capital allowances
1,031,135
910,700
Tax losses
-
(62,392)
Short term differences
(717)
(518)
1,030,418
847,790
Liabilities
Liabilities
2024
2023
Company
£
£
Accelerated capital allowances
1,031,135
910,700
Tax losses
-
(62,392)
Short term differences
(717)
(518)
1,030,418
847,790
CRAIGMARLOCH NURSERIES LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
21
Deferred taxation
(Continued)
- 30 -
Group
Company
2024
2024
Movements in the year:
£
£
Liability at 1 January 2024
847,790
847,790
Charge to profit or loss
182,628
182,628
Liability at 31 December 2024
1,030,418
1,030,418

The group had estimated tax losses available for future offset against trading profits of £Nil (2023 - £249,570).

22
Retirement benefit schemes
2024
2023
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
32,522
25,744

A defined contribution pension scheme is operated for all qualifying employees. The assets of the scheme are held separately from those of the group in an independently administered fund.

 

Contributions totalling £6,939 (2023 - £5,181) were payable to the fund at the year end and are included in creditors.

23
Share capital
Group and company
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary Shares of £1 each
127
127
127
127
24
Reserves
Revaluation reserve

The revaluation reserve represents the cumulative impact of gains and loss on freehold land and buildings held at valuation.

Profit and loss reserves

Profit and loss reserves represent accumulated comprehensive income or expenditure for the year and prior years less dividends paid.

CRAIGMARLOCH NURSERIES LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 31 -
25
Related party transactions
Transactions with related parties

During the year the group entered into the following transactions with related parties:

Sales
Purchases
2024
2023
2024
2023
£
£
£
£
Group
Other related parties
7,748,363
6,654,209
45,027
107,163
Company
Other related parties
7,723,415
6,654,209
42,783
107,163

The following amounts were outstanding at the reporting end date:

Amounts due to related parties
2024
2023
£
£
Group
Other related parties
242,765
2,820,514
Company
Other related parties
2,749,127
2,667,147

The following amounts were outstanding at the reporting end date:

Amounts due from related parties
2024
2023
Balance
Balance
£
£
Group
Other related parties
6,009
229,528
Company
Other related parties
6,009
223,613
Other information

The company has taken advantage of exemptions available under FRS 102 from the requirement to disclose related party transactions with members of a wholly owned group.

CRAIGMARLOCH NURSERIES LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 32 -
26
Directors' transactions

Interest free director loans have been provided to the group by its directors as follows:

Description
Opening balance
Amounts repaid
Closing balance
£
£
£
Directors' loans
1,112,427
(71,644)
1,040,783
1,112,427
(71,644)
1,040,783
27
Controlling party

The directors do not believe there to be an individual controlling party.

28
Cash generated from/(absorbed by) group operations
2024
2023
£
£
Profit for the year after tax
309,676
243,874
Adjustments for:
Taxation charged
213,255
131,823
Finance costs
306,237
299,665
Investment income
(822)
-
0
Depreciation and impairment of tangible fixed assets
397,675
397,179
Currency translation differences
12,241
(1,509)
Movements in working capital:
Decrease/(increase) in stocks
660,246
(936,359)
(Increase)/decrease in debtors
(2,441,330)
109,344
Increase/(decrease) in creditors
929,519
(859,443)
Cash generated from/(absorbed by) operations
386,697
(615,426)
CRAIGMARLOCH NURSERIES LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 33 -
29
Analysis of changes in net debt - group
1 January 2024
Cash flows
Other non-cash changes
31 December 2024
£
£
£
£
Cash at bank and in hand
53,840
(32,254)
-
21,586
Bank overdrafts
(121)
(637,733)
-
(637,854)
53,719
(669,987)
-
(616,268)
Borrowings excluding overdrafts
(3,500,000)
(568,180)
(147,945)
(4,216,125)
Obligations under finance leases
(708,071)
273,099
-
(434,972)
(4,154,352)
(965,068)
(147,945)
(5,267,365)
2024-12-312024-01-01falsefalseCCH SoftwareCCH Accounts Production 2025.200K T Wilson BA (Hons) CAA G McFarlaneC BegleyI DevlinfalseSC1627332024-01-012024-12-31SC162733bus:Director12024-01-012024-12-31SC162733bus:Director22024-01-012024-12-31SC162733bus:Director32024-01-012024-12-31SC162733bus:CompanySecretary12024-01-012024-12-31SC162733bus:RegisteredOffice2024-01-012024-12-31SC162733bus:Consolidated2024-12-31SC1627332024-12-31SC162733bus:Consolidated2024-01-012024-12-31SC162733bus:Consolidated2023-01-012023-12-31SC1627332023-01-012023-12-31SC162733core:RetainedEarningsAccumulatedLossesbus:Consolidated2024-01-012024-12-31SC162733core:RetainedEarningsAccumulatedLossesbus:Consolidated2023-01-012023-12-31SC162733bus:Consolidated2023-12-31SC1627332023-12-31SC162733core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2024-12-31SC162733core:ConstructionInProgressAssetsUnderConstructionbus:Consolidated2024-12-31SC162733core:PlantMachinerybus:Consolidated2024-12-31SC162733core:MotorVehiclesbus:Consolidated2024-12-31SC162733core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipmentbus:Consolidated2024-12-31SC162733core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2023-12-31SC162733core:ConstructionInProgressAssetsUnderConstructionbus:Consolidated2023-12-31SC162733core:PlantMachinerybus:Consolidated2023-12-31SC162733core:MotorVehiclesbus:Consolidated2023-12-31SC162733core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipmentbus:Consolidated2023-12-31SC162733core:LandBuildingscore:OwnedOrFreeholdAssets2024-12-31SC162733core:ConstructionInProgressAssetsUnderConstruction2024-12-31SC162733core:PlantMachinery2024-12-31SC162733core:MotorVehicles2024-12-31SC162733core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2024-12-31SC162733core:LandBuildingscore:OwnedOrFreeholdAssets2023-12-31SC162733core:ConstructionInProgressAssetsUnderConstruction2023-12-31SC162733core:PlantMachinery2023-12-31SC162733core:MotorVehicles2023-12-31SC162733core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2023-12-31SC162733core:ShareCapitalbus:Consolidated2024-12-31SC162733core:ShareCapitalbus:Consolidated2023-12-31SC162733core:RevaluationReservebus:Consolidated2024-12-31SC162733core:RevaluationReservebus:Consolidated2023-12-31SC162733core:RetainedEarningsAccumulatedLossesbus:Consolidated2024-12-31SC162733core:RetainedEarningsAccumulatedLossesbus:Consolidated2023-12-31SC162733core:ShareCapital2024-12-31SC162733core:ShareCapital2023-12-31SC162733core:RevaluationReserve2024-12-31SC162733core:RevaluationReserve2023-12-31SC162733core:RetainedEarningsAccumulatedLosses2024-12-31SC162733core:RetainedEarningsAccumulatedLosses2023-12-31SC162733core:ShareCapitalbus:Consolidated2022-12-31SC162733core:SharePremiumbus:Consolidated2022-12-31SC162733core:RetainedEarningsAccumulatedLossesbus:Consolidated2022-12-31SC162733core:ShareCapital2022-12-31SC162733core:RevaluationReserve2022-12-31SC162733core:RetainedEarningsAccumulatedLosses2022-12-31SC162733bus:Consolidated2022-12-31SC162733core:LandBuildingscore:OwnedOrFreeholdAssets2024-01-012024-12-31SC162733core:PlantMachinery2024-01-012024-12-31SC162733core:MotorVehicles2024-01-012024-12-31SC162733core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2024-01-012024-12-31SC162733core:ConstructionInProgressAssetsUnderConstruction2024-01-012024-12-31SC162733core:UKTaxbus:Consolidated2024-01-012024-12-31SC162733core:UKTaxbus:Consolidated2023-01-012023-12-31SC162733bus:Consolidated12024-01-012024-12-31SC162733bus:Consolidated12023-01-012023-12-31SC162733bus:Consolidated22024-01-012024-12-31SC162733bus:Consolidated22023-01-012023-12-31SC162733core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2023-12-31SC162733core:ConstructionInProgressAssetsUnderConstructionbus:Consolidated2023-12-31SC162733core:PlantMachinerybus:Consolidated2023-12-31SC162733core:MotorVehiclesbus:Consolidated2023-12-31SC162733core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipmentbus:Consolidated2023-12-31SC162733bus:Consolidated2023-12-31SC162733core:LandBuildingscore:OwnedOrFreeholdAssets2023-12-31SC162733core:ConstructionInProgressAssetsUnderConstruction2023-12-31SC162733core:PlantMachinery2023-12-31SC162733core:MotorVehicles2023-12-31SC162733core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2023-12-31SC1627332023-12-31SC162733core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2024-01-012024-12-31SC162733core:ConstructionInProgressAssetsUnderConstructionbus:Consolidated2024-01-012024-12-31SC162733core:PlantMachinerybus:Consolidated2024-01-012024-12-31SC162733core:MotorVehiclesbus:Consolidated2024-01-012024-12-31SC162733core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipmentbus:Consolidated2024-01-012024-12-31SC162733core:Subsidiary12024-01-012024-12-31SC162733core:Subsidiary112024-01-012024-12-31SC162733core:CurrentFinancialInstruments2024-12-31SC162733core:CurrentFinancialInstruments2023-12-31SC162733core:CurrentFinancialInstrumentsbus:Consolidated2024-12-31SC162733core:CurrentFinancialInstrumentsbus:Consolidated2023-12-31SC162733core:WithinOneYearbus:Consolidated2024-12-31SC162733core:WithinOneYearbus:Consolidated2023-12-31SC162733core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-31SC162733core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-31SC162733core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated2024-12-31SC162733core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated2023-12-31SC162733core:Non-currentFinancialInstrumentscore:AfterOneYear2024-12-31SC162733core:Non-currentFinancialInstrumentscore:AfterOneYear2023-12-31SC162733core:Non-currentFinancialInstrumentsbus:Consolidated2024-12-31SC162733core:Non-currentFinancialInstrumentsbus:Consolidated2023-12-31SC162733core:Non-currentFinancialInstruments2024-12-31SC162733core:Non-currentFinancialInstruments2023-12-31SC162733core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2024-12-31SC162733core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2023-12-31SC162733core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated12024-12-31SC162733core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated12023-12-31SC162733core:Non-currentFinancialInstrumentscore:AfterOneYear22024-12-31SC162733core:Non-currentFinancialInstrumentscore:AfterOneYear22023-12-31SC162733core:WithinOneYear2024-12-31SC162733core:WithinOneYear2023-12-31SC162733core:BetweenTwoFiveYearsbus:Consolidated2024-12-31SC162733core:BetweenTwoFiveYearsbus:Consolidated2023-12-31SC162733core:BetweenTwoFiveYears2024-12-31SC162733core:BetweenTwoFiveYears2023-12-31SC162733core:MoreThanFiveYearsbus:Consolidated2024-12-31SC162733core:MoreThanFiveYearsbus:Consolidated2023-12-31SC162733core:MoreThanFiveYears2024-12-31SC162733core:MoreThanFiveYears2023-12-31SC162733bus:PrivateLimitedCompanyLtd2024-01-012024-12-31SC162733bus:FRS1022024-01-012024-12-31SC162733bus:Audited2024-01-012024-12-31SC162733bus:ConsolidatedGroupCompanyAccounts2024-01-012024-12-31SC162733bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP